Embecta Corp. (EMBC) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Drug Manufacturers - Specialty & Generic industria. La empresa tiene su sede en Parsippany, NJ, United States. El CEO actual es Devdatt Kurdikar.
EMBC tiene fecha de IPO 2022-03-22, 2,000 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $560.22M.
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.
